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REVIEW
Abstract: The present work offers an analysis of the historical development of the discovery
and use of barbiturates in the field of psychiatry and neurology, a century after their clinical
introduction. Beginning with the synthesis of malonylurea by von Baeyer in 1864, and up to
the decline of barbiturate therapy in the 1960s, it describes the discovery of the sedative
properties of barbital, by von Mering and Fischer (1903), the subsequent synthesis of
phenobarbital by this same group (1911), and the gradual clinical incorporation of different
barbiturates (butobarbital, amobarbital, secobarbital, pentobarbital, thiopental, etc). We describe
the role played in therapy by barbiturates throughout their history: their traditional use as
sedative and hypnotic agents, their use with schizophrenic patients in so-called “sleep cures”
(Klaesi, Cloetta), the discovery of the antiepileptic properties of phenobarbital (Hauptmann)
and their use in the treatment of epilepsy, and the introduction of thiobarbiturates in intravenous
anesthesia (Lundy, Waters). We also analyze, from the historical perspective, the problems of
safety (phenomena of dependence and death by overdose) which, accompanied by the
introduction of a range of psychoactive drugs in the 1950s, brought an end to barbiturate use,
except in specific applications, such as the induction of anesthesia and the treatment of certain
types of epileptic crisis.
Keywords: barbiturates, history of medicine, sedative-hypnotic drugs, “sleep cures”, epilepsy,
anesthesia
Introduction
Throughout the history of humanity, numerous therapeutic agents have been employed
for their hypnotic and/or sedative properties, though the true effectiveness of many
of them has been fairly limited (Alamo et al 1998). It suffices to mention alcohol
itself (in different forms, such as hydromel or wine) or the alkaloids of opium and
other narcotic plants (hemp, jimsonweed, belladonna, henbane, etc). More recently,
around the late 19th and early 20th centuries, agents such as paraldehyde, chloral
hydrate, and bromides were used, until the discovery, at the beginning of the 20th
century, of the sedative and hypnotic properties of barbiturates, thanks to the prior
synthesis of malonylurea by Adolf von Baeyer in 1864.
The clinical introduction of barbiturates begun a century ago (1904) when the
Farbwerke Fr Bayer and Co brought onto the market the first agent of this type,
diethyl-barbituric acid, giving rise to profound changes in the pharmacological
approach to the psychiatric and neurological disorders of the time. A large number
of previously untreatable patients gained access to treatment and improved their
prognosis. The most significant results were obtained in the treatment of patients
with serious neuroses and psychoses and with severe emotional repression, who as a
result of being administered barbiturates, especially intravenously, overcame their
inhibitions, thus facilitating psychotherapeutic treatment. Barbiturates were also useful
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pharmacological tools for the management of epileptic
seizures. Furthermore, they opened up the field of
intravenous anesthesia, playing a prominent role in
anesthetic induction, above all for minor operations.
In the course of the 20th century, more than 2500
barbiturates were synthesized, 50 of which were eventually
employed clinically. Their use was widespread and many
still have some use today. One hundred years after the
introduction in clinical pharmacology of the original
compound, oxybarbiturates, in general, continue to be the
selected drugs in the treatment of some serious forms of
insomnia and in some types of epilepsy. Similarly, some
thiobarbiturates and some ultrashort-acting barbiturates are
still used today as inducers of general anesthesia.
Nevertheless, currently, 5 or 6 derivates of barbiturates are
sufficient to cover the therapeutic applications that still
require them.
Sedative and anticonvulsant drugs
in the pre-barbiturate era
Although, as mentioned, the therapeutic agents historically
employed for their sedative, hypnotic, or anticonvulsant
effects have been quite numerous, the most specific drugs
in this regard have their origin in the 19th century. Such is
the case of choral hydrate, different alkaloids and, above
all, bromides (Hollister 1983; Sneader 1985; Scott 1992;
Lehmann 1993; Shorvon and Sander 1996; Shorter 1997;
Alamo et al 1998; Healy 2002).
The second half of the 19th century is called by some
authors, such as Shorter (1997), the “alkaloids era”.
Alkaloids were introduced into psychiatry as sedatives and
hypnotics, thanks to the isolation of morphine from opium,
in 1805, by the German pharmacist Friedrich Sertürner. In
1861, Wilhelm Griesinger, in the second edition of his Die
Pathologie und Therapie der Psychischen Krankheiten,
defended the use of opium in sleep disorders, pointing out
the improvements it brought about in patients suffering from
anxiety. However, the alkaloids that met with most success
were those isolated from different species of the Solanaceae
family: plants known for their hallucinogenic effects, such
as hyoscyamus, whose sedative and hypnotic properties were
described by the Viennese pharmacologist Karl Schroff in
1868. In 1839, chemists at the E Merck company in
Darmstadt (Germany) had already isolated hyoscyamine,
another alkaloid, which became popular in the late 19th
century, forming part of many of the “cocktails”
administered in neuropsychiatric institutions at that time
(Woodward 1994). Finally, the year 1880 saw the isolation
of hyoscine (called scopolamine in North America), an
alkaloid that was also widely used in psychiatric cocktails,
such as the famous Hyoscine Co A, which contained
hyoscine, morphine, and atropine, and was administered to
highly excited and aggressive manic patients (Norton 1979).
The first drug that could truly be called hypnotic is
chloral hydrate. Synthesized in 1832 by Justus von Liebig,
a chemist from Giessen, it was not analyzed as a hypnotic
until 1869 by the Berlin pharmacologist Oskar Liebreich.
The hypothetical mechanism to which its action was ascribed
was based on the mistaken belief that, in vivo, chloral hydrate
was capable of transforming itself into formic acid and
chloroform, whose properties were already known at that
time (Sourkes 1992). Very soon, chloral hydrate substituted
morphine and the Solanaceae alkaloids, given its
convenience, as it could be administered without the need
for injection, allowing treatment in the home and making it
unnecessary to confine patients to neuropsychiatric
institutions (Shorter 1997).
Nevertheless, it would be the bromides that were most
widely used in the second half of the 19th century, either as
sedatives or for the treatment of epilepsy, having been
introduced for these applications by the internist and
obstetrician Sir Charles Locock in 1857. It was in that year
that Locock reported his results in the treatment with
bromides in women with what the author has named as
catamenial or hysteriform epileptic seizures, obtaining
positive outcomes in 14 women out of a sample of 15. From
that time on, bromides were widely introduced in asylums
and similar institutions throughout Europe, given their
sedative and antiepileptic properties, the relevant function
in the latter case being to reduce the expression of the
epileptic patients’ sexuality. Another contribution in relation
to the neuropsychiatric use of bromides was made by the
British doctor Neil MacLeod, who in 1897, while working
in Shanghai, carried out the first “sleep cure” with these
salts. MacLeod called it “the bromide sleep” (MacLeod
1900), and some authors, such as Shorter (1997), have
considered this technique as the first pharmacological
therapy that, within psychiatry, succeeded in improving the
symptoms of psychiatric patients. However, the main
problem with bromides resided in their high toxicity
(neurological and gastrointestinal disorders, irritability,
hallucinations, deliria, and lethargy), given their long half-
life (elimination taking around 12 days) and their capacity
for accumulation in tissue; as a result, they were gradually
phased out after the introduction of barbiturates in the early
part of the 20th century (Balme 1976).Neuropsychiatric Disease and Treatment 2005:1(4) 331
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Other substances used as hypnotics and sedatives and
eventually as anticonvulsants were also introduced in the
19th century and the early decades of the 20th century. Such
is the case of paraldehyde, discovered by Wildenbusch in
1829 and introduced into clinical practice by Vincenzo
Cervello in 1882; and sulphonal, whose hypnotic action was
discovered by chance by Eugen Baumann and Alfred Kast
in 1887 (Kast 1888). Finally, those seeking to treat epilepsy
turned, as well as to potassium bromide, chloral hydrate, or
hyoscine, to a whole host of substances of more questionable
efficacy, including opium, belladonna, atropine,
stramonium, strophanthus, cannabis indica, and zinc oxide.
The discovery and clinical
introduction of barbiturates as
sedative and hypnotic agents
Between the 1920s and the mid-1950s, practically the only
drugs used as sedatives and hypnotics were barbiturates
(Lehmann and Ban 1970). From a chemical point of view,
these drugs are closed-chain ureic compounds, whose
nucleus is malonylurea (a combination of urea, a product
present in animal excrement, and malonic acid, an acid
derivative taken from apples) (Figure 1). Barbiturates were
synthesized in 1864 by Adolf von Baeyer, though the
synthetic process was developed and perfected by the French
chemist Edouard Grimaux in 1879, making possible the
subsequent widespread development of barbiturate
derivatives (Carter 1951). Von Baeyer, a disciple of Robert
W Bunsen and Friedrich A Kekulé, taught at the universities
of Strasbourg and Munich, was the founder of what was to
become the Bayer Chemical Co, and received the Nobel
Prize in Chemistry in 1905 for his contribution to the
development of organic chemistry (Figure 2a).
There are various hypotheses about the origin of the term
“barbiturates” (Dundee and McIlroy 1982). According to
one of these, Baeyer may have used this name for the
compounds for sentimental reasons, in honor of his friend
Barbara (Cohen 1943). Other authors, however, claim that
the name derives from the fact that Baeyer celebrated his
discovery in a tavern near his home that was frequented by
artillery officers, who themselves were celebrating the day
of their patron, St Barbara (Sharpless 1970). A third
possibility is that the term is inspired by the “barbed”
appearance of the crystals of these ureic compounds (Fieser
1944). In any case, it is clear that the union of the elements
“barb(ara)” and “urea” forms the basis of the name.
Figure 1 Synthesis of barbituric acid, from the combination of malonic acid
(left) and urea (right).
Figure 2 (a) Adolf von Baeyer (1835–1917); (b) Josef von Mering (1849–1908); (c) Emil Fischer (1852–1919).
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From malonylurea to barbital
The first of the barbiturates to come onto the market was
diethyl-barbituric acid, also known as barbital, malonal, or
gardenal. Synthesized in 1881 by Conrad and Guthzeit, on
treating the argentic salt of barbituric acid with ethyl iodide,
it was introduced clinically as a hypnotic by the German
companies E Merck (Darmstadt) and F Bayer and Co
(Elberfeld) in 1904, thanks to the work of Josef Freiherr
von Mering (Figure 2b) and Emil Fischer (Nobel Prize in
Chemistry, 1902) (Figure 2c).
Von Mering, who taught pharmacology at the University
of Halle, had observed that some of the synthetic compounds
obtained towards the end of the 19th century and
commercialized as hypnotics, such as sulphonal, contained
in their molecular structure a carbon atom with two ethyl
groups. Furthermore, knowing of von Baeyer’s work with
derivatives of urea, von Mering decided to study the hypnotic
properties of diethyl-acetylurea, and found that it was even
more potent than sulphonal. The next step was to analyze
the properties of 5,5-diethyl-barbituric acid, for which he
turned to Fischer, an old friend from his student days. At
that time, Fischer, doyen of the German organic chemists,
was Professor of Chemistry at the University of Berlin.
Moreover, Fischer was well acquainted with the chemistry
of malonylurea, as he had been von Baeyer’s assistant in
Munich for eight years. Together with his nephew Alfred
Dilthey, he tested the new, resynthesized product,
demonstrating, in dogs, that its hypnotic power was far
greater than that of von Mering’s diethyl-acetylurea (Sneader
1985). When Fischer told his friend von Mering about this
finding, the latter happened to be in the Italian city of Verona,
and it was this that prompted him to call the new drug
Veronal
® (Cohen 1943; Sharpless 1970). Nevertheless, other
authors argue that the name Veronal (from Latin,
verus = true) was coined by Fischer, who claimed to have
found the “true” hypnotic compound (Sneader 1985). This
new hypnotic drug was patented by Fischer in January 1903,
and two months later the first scientific data on barbiturates
were published in a brief report (Fischer and von Mering
1903). The licence for its commercialization in the USA
was granted to the Winthrop Chemical Company.
The term barbital for diethyl-barbituric acid is a later
development, coming as a result of the economic effects of
World War I. After the United States entered the conflict, in
1917, Congress passed the Trading with the Enemy Act
1917, which permitted them as a kind of war booty to
manufacture German products protected by patent,
modifying their generic name and with the profits going to
the American subsidiaries of the German companies
(Sneader 1985). Thus, the American Medical Association
approved the name barbital, whilst in the United Kingdom,
through a similar mechanism, diethyl-barbituric acid came
to be called barbitone. From this point on the two endings
“-al” and “-one” could be found in the nomenclature of
barbiturates.
Veronal had hypnotic, sedative, and anticonvulsant
properties (Figure 3a). It could calm manic patients and help
melancholic patients to sleep, and was an effective inducer
of sleep in insomniacs. The first trials with barbital were
carried out by Hermann von Husen (1904), a young
psychiatrist affected by sleep disorders, who tried the new
drug on himself. After taking 0.5 g of Veronal the first night
and 1 g the following night, he reports:
In both cases, after 10–15 minutes, I fell into a growing
state of dejection that led to deep sleep after around 30
minutes. After half a gram of Veronal I slept for 8 hours,
and after a whole gram, around 9 hours. On the first
morning I awoke fresh and rested; on the second morning,
after the higher dose, I found it difficult to get out of bed
(von Husen 1904, p 59).
The consolidation of barbiturate
therapy: phenobarbital
By means of small modifications to the chemical structure
of the barbituric acid molecule, more than 2500 different
agents were synthesized. The first barbital analogs,
numbering around 18, were synthesized and tested by the
group made up of von Mering, Fischer, and Dilthey. One of
them, perhaps that most widely used subsequently, was
phenobarbital, synthesized by Hörlein in 1911, on
substituting one of the ethyl groups by a phenyl radical.
Phenobarbital was employed in therapy as a hypnotic for
the first time in 1912 by Loewe, Juliusburger, and Impens,
and that same year it was commercialized by F Bayer and
Co, under the name Luminal
®. Phenobarbital, with a more
prolonged pharmacological action than its predecessor, soon
became “king of the barbiturates”, both in hospitals and in
outpatient care (Shorter 1997). This drug opened up the way,
moreover, to another important therapeutic application of
barbiturates, as will be mentioned later: the treatment of
epilepsy.
Both Veronal (barbital) and Luminal (phenobarbital), the
first two representatives of the series of barbiturates, were
accepted by the international pharmacopoeia, such as the
United States Pharmacopoeia (USP X) in 1926, and the
British Pharmacopoeia in 1914 and 1932, respectively.Neuropsychiatric Disease and Treatment 2005:1(4) 333
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Later, both drugs were also included in the Pharmacopoeia
Internationalis.
Clinical introduction of the new
barbiturates
The new barbiturates brought substantial advantages
compared with their classical predecessors, such as a greater
potency and duration of action, as well as a wider therapeutic
range. However, of the several thousand that were
synthesized, only about 50 came onto the market, and of
these no more than a couple of dozen were regularly used
in clinical practice. The next barbiturate to be used
successfully in therapy was butobarbital, whose history
begins in World War I. The British war effort required large
quantities of acetone for the manufacture of explosives
(Sneader 1985), and one of the solutions was provided by
Chaim Weizmann, who would later become the first
president of the state of Israel. Weizmann found that the
bacteria Clostridium acetobutylicum was capable of
transforming materials rich in starch into acetone and butyric
alcohol, and at low industrial cost. After the war, the cost of
butyric alcohol, a chemical that was as useful as it was
expensive, fell drastically, thus permitting its use for
obtaining numerous synthetic drugs. In 1920, Roger Adams
(Abbott Laboratories, Chicago, USA) synthesized the ester
of 5-butyl-5-ethyl-malonic acid, an intermediate stage in
the synthesis of a butyl analog of barbital, which was finally
synthesized by Arthur Dox (Parke Davis and Company,
Detroit, USA) in 1922, and marketed the following year by
Abbott Laboratories, under the name Neonal
® (Sneader
1985). Butobarbital (butethal in the USA) was three times
as strong as barbital and its period of action was much shorter
due to its lipophilicity, which greatly lowered the possibility
of “rebound” drowsiness the day after administration.
In the years that followed, new barbiturates continued
to come onto the market. In 1923, it was amobarbital
(Amytal
®), synthesized by Shonle and Moment (Eli Lilly
Company, Indianapolis, USA) by adding a carbon atom to
the butyl chain of butobarbital; and in 1929, Horace A
Shonle also synthesized secobarbital (Seconal®). Both
barbiturates had quite similar pharmacological properties
to those of butobarbital (Sneader 1985). The next drugs of
this series to be introduced were pentobarbital (Nembutal
®),
synthesized by Volwiler and Tabern (Abbott Laboratories)
in 1930, and thiopental (Pentothal
®). The latter, a sulfur
derivative of pentobarbital, presented at the American
Chemical Society congress in San Francisco in August 1935
(Tabern and Volwiler 1935), would revolutionize intravenous
Figure 3 (a) Elixir Veronal from Dr Bustamante’s Laboratories it is a “Practical treatment of insomnia”. They have also added audaciously “Secure and harmless”.
Finally they say that “it tastes good and acts smoothly, being absorbed by the organism”. (b) Advertisement for Abbott sodium pentobarbital in an American medical
journal of 1933, highlighting its “short but powerful hypnotic effect and prolonged sedative action from small dosage”.
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anesthesia and would be the only representative of the
thiobarbiturate family to be officially recognized, being
accepted first by the British Pharmacopoeia (1942, 7th Add)
and subsequently by the United States Pharmacopoeia
(1947, USP XIII) and the Pharmacopoeia Internationalis
(1951, Volume I). Figure 3b shows an advertisement for
pentobarbital in an American journal of the time.
Table 1 shows the recommended dosages of barbiturates
used as hypnotics together with those of other drugs also
used as hypnotics prior to the clinical introduction of
benzodiazepines at the end of the 1950s. Among these last
agents, chemically different from barbiturates although with
similar pharmacological actions, we have to mention
glutethimide (USV Pharmaceutical Corporation, 1954),
methyprylon (Hoffmann-La Roche, 1955), methaqualone
(King George Medical College, Lucknow, India, 1956;
William H Rorer Inc, 1965), chlormethiazole (Hoffmann-
La Roche, 1956), and ethchlorvynol (Pfizer, 1956). Most
of these drugs were introduced as barbiturate substitutes,
due to the fact that they seemed to offer a wider margin of
safety. However, the clinical experience has demonstrated
that their addiction liability and the severity of withdrawal
symptoms were similar to those of barbiturates, and most
of them were removed from the market some years later.
The role of barbiturates in “sleep
cures” for schizophrenic patients
The hypnotic properties of some barbiturates were rapidly
applied to the treatment of psychotic patients, thanks to their
induction of a state of deep and prolonged sleep. The pioneer
of these techniques was the Italian psychiatrist Giuseppe
Epifanio, working at the University Psychiatric Clinic in
Turin, who described his technique in an article published
in 1915. The lack of impact of this development on the
international scientific community can be attributed to the
fact that it was published only in an Italian journal, and in
the middle of the Great War (Epifanio 1915). It was on 25th
March 1913 that Epifanio administered the first dose of
Luminal to a girl aged 19 (FL) affected by manic-depressive
psychosis, extending the treatment over a period of 4 days.
The patient fell into a “deep sleep” that lasted until 9th April,
was discharged at the end of June, and was in remission
during the next two years. This case marked the beginning
of what Manfred Bleuler would describe in 1955 as “the
first of the great physical therapies” for mental disorders
(Windholz and Witherspoon 1993).
However, the clinical introduction of these techniques
is historically associated with Jakob Klaesi, a psychiatrist
at the University Psychiatric Clinic in Zurich (Psychiatrische
Universitätsklinik, Burghölzli, Switzerland). His “sleep
cures” (“Dauerschlaf”, “Dauernarkose”), proposed in 1920
within the framework of the 59th Assembly of the Swiss
Psychiatry Society (28th November 1920), enjoyed great
prestige at the time and directly involved the use of
barbiturates. Klaesi’s initial proposal was that his techniques
for inducing deep hypnosis, taken from Epifanio, would
facilitate communication between patient and psycho-
therapist (“to achieve a better relationship between doctor
and patient”) (Shorter 1997, p 204). Klaesi introduced his
method in Switzerland, and based it on pre-medication with
morphine (0.01 mL) and scopolamine (0.001 mL) and the
subsequent administration (intravenous or subcutaneous),
over at least 6–7 days, of Somnifen
® (Figure 4), a mixture
of diethyl and dipropenyl-barbituric acid and diethylamine
(2–4 mL), manufactured by the Hoffmann-LaRoche
company. The percentage improvements reported by Klaesi,
in samples of schizophrenic patients, ranged from 25% to
33%, which is 10% higher than the rates of spontaneous
remission in this type of patient (Klaesi 1922). These cures
(“prolonged sleep therapy”) acquired great popularity during
the 1920s, with numerous variations as regards methodology
and applications (agitated schizophrenic patients, delirium
tremens, autism, morphine dehabituation, etc), though the
administration of Somnifen was always involved (Windholz
and Witherspoon 1993). Nevertheless, it is important to
consider a fact mentioned in the first publication on the
effectiveness of the method in schizophrenic patients: three
of the 26 patients recruited died during the study due to
Table 1 Mean and maximum dosage of the pharmacological
agents used as hypnotics before the benzodiazepine era
Dosage per administration Daily
Mean Maximum maximum
Drug dosage dosage dosage
Ethchlorvynol 250 mg 500 mg 750 mg
Chloral hydrate 500 mg 1000 mg 1000 mg
Paraldehyde 3 mL 8 mL 8 mL
Glutethimide 250 mg 500 mg 500 mg
Methyprylon 200 mg 400 mg 400 mg
Methaqualone 200 mg 400 mg 600 mg
Phenobarbital 50–100 mg 200 mg 200 mg
Amobarbital 50–100 mg 200 mg 200 mg
Secobarbital 100 mg 200 mg 200 mg
Pentobarbital 100 mg 200 mg 200 mg
Sodium tripental 250 mg 500–1000 mg –
NOTE: The doses indicated correspond only to the hypnotic use of these drugs.
The maximum doses of the barbiturates are not considered when they are used
as anticonvulsants.Neuropsychiatric Disease and Treatment 2005:1(4) 335
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bronchopneumonia or hemorrhages in the cardiac muscles
(Klaesi 1922). A few years later, some authors set the
mortality rate with Somnifen at around 5% (Müller 1927).
The legacy of Somnifen was taken up at the same Swiss
clinic in Burghölzli by pharmacologist Max Cloetta and
psychiatrist Hans W Maier, who sought a compound that
would be better tolerated. In 1934, they prepared a
compound based on paraldehyde, amylen hydrate, chloral
hydrate, alcohol, ephedrine hydrate, digalen, and isopropyl-
allyl-barbituric acid, which they called Cloettal
® or “Cloetta
Mixture”, and which was rectally administered (Cloetta and
Meier 1934). This preparation was widely used in
schizophrenic patients, not only in the Zurich clinic (Boss,
Monnier), but also elsewhere, such as in the Soviet Union
by Ivan P Pavlov (Windholz and Witherspoon 1993). The
most rigorous study with this mixture was carried out in
Burghölzli by Marcel Monnier, who, with a sample of 125
schizophrenic patients, applied strict exclusion criteria
(elderly patients and those with renal or respiratory
disorders) before applying the preparation. Only 84 patients
were given the Cloetta Mixture, and 53 of them improved
(40 were even discharged from the hospital). Nevertheless,
two patients died during the treatment as a result of
respiratory complications associated with the medication
(Monnier 1936).
Eliot Slater, of the Maudsley Hospital in London,
recalled that “sleep cures” were “the only treatment we had
back in the 1930s that was of any value in acute psychotic
disorders” (Slater 1975, p 74). After this initial period, the
use of “sleep cures” based on barbiturates began to decline
due in part to problems of safety, as well as to the clinical
introduction of new biological therapies for the treatment
of schizophrenic patients such as Sakel’s (1935) insulin
shocks or the cardiazolic shocks of von Meduna (1937).
Even so, as Shorter (1997) points out, “the story of barbituric
narcosis has a corollary”. This refers to the work of D Ewen
Cameron in the mid-1950s at the Psychiatry Department of
the Allan Memorial Institute in Montreal (Canada). Financed
by the Central Intelligence Agency (CIA), Cameron
developed his technique of “psychic driving” (Cameron
1956), a prototype version of what would come to be known
commonly as “brainwashing”. With this technique, in which
barbiturates were also used, Cameron intended to take
advantage of prolonged sleep to force his patients to listen
to propaganda messages, which, in this case, were designed
to quicken their recovery. In spite of its aims, eminently




With phenobarbital, in addition to confirmation of the
excellent hypnotic effect of barbiturates, it was demonstrated
that these drugs had significant anticonvulsant properties.
The discovery of these properties took place in 1912, the
year of their commercialization, and provided another
example of serendipity in the field of psychopharmacology.
Alfred Hauptmann, resident psychiatrist in Freiburg, was
given responsibility for the care of epileptic inpatients.
Finding it impossible to sleep properly because of the
continual convulsive seizures of his patients, Hauptmann
decided to administer them some of the new hypnotics on
the market, among them phenobarbital. Surprisingly,
Hauptmann observed that the incidence of seizures in
patients treated with low doses of phenobarbital fell notably,
not only during the night, but also during the day
(Hauptmann 1912). One of Hauptmann’s most important
conclusions was that phenobarbital not only reduced the
number of seizures, but also their intensity, allowing many
patients to leave the institutions and enjoy a normal working
life.
It was in this way that the anticonvulsant properties of
barbiturates were discovered, phenobarbital being the first
truly effective drug for the treatment of epilepsy (Iváñez
and Díez-Tejedor 1998). Table 2 shows, by way of example,
Figure 4 The packaging of Somnifen
®, produced by Hoffmann-LaRoche.Neuropsychiatric Disease and Treatment 2005:1(4) 336
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the anticonvulsant agents commonly employed in the
treatment of epilepsy before and after the introduction of
phenobarbital.
However, the international acceptence of phenobarbital
as an antiepileptic drug was seriously delayed, due first of
all to the scarce significance outside Germany of the journal
in which Hauptmann published the reports of his work
(Münchener Medizinische Wochenschrift), and secondly, to
the outbreak of World War I. Indeed, phenobarbitone was
not commercialized in Great Britain until 1923, by the
Winthrop Chemical Company. In one of his first reports on
the use of phenobarbitone in England, Charles Brooks,
Colony Medical Officer at the Chalfont Centre in London,
noted its particular efficacy in severe cases of convulsions
and in epileptic conditions with associated mental deficiency.
Brooks also mentioned that if the barbiturate did not show
a certain degree of effectiveness in the first months of
treatment, the result of the therapy would not be satisfactory,
so that it would be necessary to find an alternative (Brooks
1922). In a later report, Brooks made a close examination
of patterns of use of phenobarbitone, concluding that it was
more effective than bromides, but that it was not particularly
useful in patients with low-intensity seizures (Brooks 1923).
It was precisely the Chalfont Centre that published, at
the end of the 1920s, one of the first therapeutic guides for
newly admitted epileptic patients, written by F Haward
(Shorvon and Sander 1996). According to this guide,
potassium bromide was the first-choice treatment, though
it should be substituted by phenobarbital if there was no
remission in the seizures within a given period of time (Table
2). If after three months of treatment the improvement was
not clear, the guide recommended treatment with a
combination of Luminal
® and potassium bromide.
Moreover, it set down the recommended dosage for pheno-
barbitone: 1 grain (65 grams) in the morning and another at
night for adult patients, and 1/2 grain in the case of children;
the dose was to be increased gradually, according to the
clinical response, but should never exceed 6 grains per day
(Haward 1928). At the beginning of the 1930s, the use of
phenobarbital superseded definitively that of bromides in
the treatment of epileptic seizures, despite the first reports
of pharmacological tolerance and the risk of seizures when
withdrawal was too abrupt. Phenobarbital is currently the
most widely-prescribed antiepileptic drug in the world
(Shorvon 2000), even though in the developed countries it
has passed onto a secondary plane in therapy, for the
treatment of partial and generalized seizures, due to its
profile of adverse effects.
In the years following the discovery of the antiepileptic
properties of phenobarbital, there were studies of numerous
barbiturate derivatives in the field of epilepsy, the most
important being mephobarbital (Prominal
®) (Weese 1932)
and, above all, deoxybarbital or primidone (Mysoline
®).
Primidone was synthesized by Bogue and Carrington
(Imperial Chemical Industries Ltd, ICI, Manchester, UK)
in 1949, demonstrating its antiepileptic activity in patients
with generalized seizures in 1952 (Handley and Stewart
1952). Initially, primidone awoke great therapeutic interest,
as it was thought that its anticonvulsant effectiveness may
be greater than that of other available barbiturates, and
without sedative effects (Bogue and Carrington 1953), but
this interest soon waned after it was demonstrated that
phenobarbital was a metabolite of this drug, together with
phenyl-ethyl-malonamide (Butler and Waddell 1956).
Comparative clinical studies carried out with phenobarbital
and its prodrug, primidone, showed no differences between
Table 2 Anticonvulsant drugs used at the National Hospital (Queen Square) in London, before and after the clinical introduction
of phenobarbital in the treatment of epilepsy
1910 1930
Drugs of Drugs of Drugs of Drugs of
definite benefit doubtful benefit definite benefit doubtful benefit
Bromides Monobromate of camphor Bromides Zinc salts
Chloral hydrate Eosinate of sodium Bromide combinations Iron
Glycerophosphates Chloretone Phenobarbital Digitalis
Borax Antipyrin Borax Strophanthus
Belladonna Double tartrate of Calcium
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the two (Oleson and Dam 1967). Currently, primidone is
still considered as being of some use in partial and secondary
generalized seizures, but is not a first-choice drug. Unlike
phenobarbital, it cannot be used in epileptic status, since no
galenic formulation has been developed for its parenteral
administration.
The discovery by Houston Merritt and Tracy Putnam
(Boston City Hospital, USA) in 1938 of the anticonvulsant
properties of phenytoin (the first drug to show that an
antiepileptic need not be a hypnotic), in 1944 of
trimethadione, and in the late 1950s of carbamazepine,
extended the spectrum of antiepileptic drugs, resulting in
decreased use of barbiturates in these applications.
The use of barbiturates in
intravenous anesthesia
Despite the existence of some publications on the use of
Somnifen
® as a general anesthetic as early as 1921 by the
French anesthetist Daniel Bardet – who noted that his
patients woke up very slowly and with serious headaches
(Bardet 1921) – the first barbiturate to be used systematically
in anesthesia was sodium sec-butyl-(2-bromo-allyl)-
barbiturate (Pernocton
®). This was introduced into the field
by the German obstetrician Bumm in 1927 (Bumm 1927).
Subsequently, as new barbiturates were synthesized for their
oral administration as sedatives, sodium salts of the same
drugs were formulated, which could be administered
intravenously and used as anesthetics (Dundee and McIlroy
1982). Notable among the pioneers in this field is John S
Lundy of the Mayo Clinic (Rochester, USA), who
introduced sodium amobarbital (1929) and sodium
pentobarbital (1930) in anesthesia.
The addition of a methyl group to the butobarbital
molecule, by the chemists Kropp and Taub at Bayer (IG
Farbenindustrie, Leverkusen) in the early 1930s, gave rise
to hexobarbital, whose sodium salt (Evipal®), introduced
into clinical anesthesia in 1932 (Weese and Scharpff 1932),
constituted the first barbiturate agent that induced anesthesia.
Ten years after its introduction, more than 10 million people
had undergone operations with the help of this drug (Adams
1944). The duration of hexobarbital’s action was shorter
than that of its predecessors, given its greater lipophilicity,
but under its effect some muscular movements occurred.
This problem was solved through the next modification of
the chemical structure of the basic nucleus of the
barbiturates, the addition of a sulfur group to pentobarbital.
Thus born were the agents that would revolutionize
intravenous anesthesia, the thiobarbiturates, thanks to the
work of Volwiler and Tabern of Abbott Laboratories (Tabern
and Volwiler 1935). These agents were studied as anesthetics
at the Mayo Foundation (Rochester) by John Lundy’s group,
who gave the sulfur derivative of pentobarbital the name
Thionembutal
®. Its sodium salt was marketed as Pentothal
(Figure 5). The team led by Ralph M Waters at the University
of Wisconsin Medical School (Madison, USA) were the
first to begin clinical administration of Pentothal, and
published their results in 1936 (Pratt et al 1936). This agent
rapidly displaced the rest of the barbiturates as an anesthetic,
partly due to the swiftness of its onset and its short action
period, and it currently remains the preferred intravenous
anesthetic in many types of surgical intervention. Despite
the anesthetic efficacy of both hexobarbital and thiopental,
the barbiturates most commonly employed in surgery in the
mid-20th century, they were not without their clinical
problems. Such problems were brought to the public eye in
particularly unfortunate fashion after the involvement of
these agents, apparently due to malpractice, in numerous
cases of death in patients treated in states of shock after the
Japanese attack on Pearl Harbor in December 1941. Some
authors went as far as describing these drugs as providing
the “ideal form of euthanasia” (Halford 1943).
After World War II the search for anesthetic barbiturates
continued, and new compounds such as thiobutobarbital
(Horatz and Stürtzbecher 1952) were introduced, though
the only one that truly challenged thiopental was
methohexital (Brietal
®), developed by SM Chernish’s group
at Lilly Research Laboratories (Indianapolis, USA) in 1956.
In clinical trials, methohexital showed itself to be more
potent than thiopental and to lead to quicker recovery in
patients; it was recommended for use as an anesthetic
Figure 5 The packaging of Abbott Pentothal® at the time of its clinical
introduction in the late 1930s. Pieces from the Museum of the Buenos Aires
Anaesthesiology Association (Argentina).Neuropsychiatric Disease and Treatment 2005:1(4) 338
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inducer in minor outpatient surgery (Taylor and Stoelting
1960). The subsequent development of other anesthetic
agents for intravenous administration (hydroxydione,
alphaxalone, etomidate, propofol, etc) led to a reduction in
the use of barbiturates in this context.
The peak and decline of
barbiturate therapy
As mentioned earlier, chemists from different universities
and pharmaceutical companies managed to synthesize over
2500 barbiturate derivates. The differential pharmacokinetic
properties of these agents made it possible to draw up a
practical clinical classification, based on the duration of their
pharmacological action (Hollister 1983). Thus, the
barbiturates in the category of short or intermediate action
(secobarbital, amobarbital, pentobarbital) were employed
initially as hypnotics, whilst those of prolonged action
(phenobarbital) were widely used as anxiolytics and
anticonvulsants; ultrashort-acting agents, notably sodium
thiopental, were especially useful as anesthetic inducers for
minor operations (Table 3). From time to time, some
barbiturates have been used in the treatment of other
disorders. One such case is the use of primidone in the
management of essential tremor (Koller et al 2000), while
another is that of combinations of barbiturates and analgesics
(salicylates, codeine, etc) in the treatment of headaches,
migraines, and other types of pain (Wolf et al 1941), though
such applications are considered counterproductive today.
Some barbiturates, such as sodium amytal and sodium
pentothal (the latter being known as “the truth serum”) were
widely known and used as coadjuvant agents for the exercise
of narcoanalysis, as initially developed by Bleckwenn in
1930 (Bleckwenn 1930a, 1930b). In principle, the
application of an infusion of barbiturates reverted
temporarily the catatonic state of certain schizophrenic
patients. These cures for catatonia allowed patients, for a
few hours, to maintain conversations and interact with their
environment, before returning to their state of lethargy.
Despite the fact that the response was somewhat brief, these
cures were quite customary in European asylums in the
1930s and 1940s. But a variety of this technique became
widespread during and after World War II: it consisted of
the intravenous administration of a short-acting barbiturate,
which had a disinhibiting effect (potentiating positive
transfers) and facilitated the subsequent exercise of
psychotherapy (a phenomenon referred to as “cathartic
abreaction”) (Lehmann 1993). This technique was also
called by other authors the “induced crepuscular method”.
It was during the 1930s and 1940s that barbiturates
attained their greatest popularity and were most widely used,
putting them in a position that could be compared, according
to Hollister (1983), to that currently held by benzo-
diazepines. The barbiturates most commonly used at that
time were phenobarbital, sodium amobarbital, sodium
secobarbital, sodium pentobarbital, and sodium thiopental.
Despite their widespread use during the first half of the 20th
century, no barbiturate succeeded in eliminating the main
drawbacks of these drugs, which were the phenomena of
dependence and death by overdose (Johns 1977). Among
the paradoxes of destiny is the possible death through
overdose of the two scientists who introduced the first
barbiturate, Fischer and von Mering, after some years of
dependence upon these substances (Escohotado 1996). To
reduce these problems, from a legal perspective, a series of
laws were passed aimed at regulating the distribution and
sale of barbiturates. The first of these came into force in
California in 1929. However, its effects were limited, if we
consider, for example, that the production of barbiturates in
the USA increased by more than 400% from 1933, with
some 70 tons of these drugs sold in 1936. The problem
continued during the following decade, and it became
necessary to arrange special conferences for all those
involved, such as that held in Washington, under the auspices
of the American Pharmaceutical Association, on 12th
October 1945 (Conference on the Regulation of Use and
Distribution of Barbiturates). Barbiturate use in the pre-
benzodiazepine period was such that, in the USA alone,
production of these drugs reached, in 1955, the quantity
Table 3 Classification and principal clinical applications of the barbiturates most commonly employed before World War II
Barbiturates Trade name Chemical name Clinical indications
Long-acting Phenobarbital Luminal 5-ethyl-5-phenylbarbituric acid Sedative
Intermediate-acting Amobarbital Amytal 5-ethyl-5-isopentylbarbituric acid Hypnotic
Short-acting Pentobarbital Nembutal 5-ethyl-5-(1-methylbutyl)-barbituric acid Hypnotic and anticonvulsant
Secobarbital Seconal 5-allyl-5-(1-methylbutyl)-barbituric acid Hypnotic
Ultrashort-acting Thiopental Pentothal 5-ethyl-5-(1-methylbutyl)-thiobarbituric acid Anesthesia inducer
Adapted from Hollister (1983).Neuropsychiatric Disease and Treatment 2005:1(4) 339
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necessary for the treatment of 10 million people throughout
an entire year. Figure 6 shows the industrial production of
barbiturates and their derivatives in the USA during the
1940s and 1950s.
The capacity of barbiturates to cause dependence was
described in the medical literature as early as one year after
the commercialization of barbital (“the Veronal habit”),
though reliable evidence of the potential of these drugs to
generate abuse was not available until the 1950s (Glatt
1962). In fact, doses 4–6 times higher than the therapeutic
dose as hypnotics of the short-acting barbiturates (400–
600 mg/day of amobarbital, secobarbital, or pentobarbital)
brought about, if the treatment was sufficiently prolonged,
authentic withdrawal syndromes when use was stopped. In
order to palliate these effects, the Narcotics Expert
Committee at the World Health Organization recommended
(at their sessions of 7th–12th January, 1952, and 18th–24th
October, 1956) that barbiturates should only be available
on medical prescription. In spite of this, and according to
different estimates, in 1965 there were 135 000 barbiturate
addicts in England, whilst in the United States it was
declared, by a special drug-dependence committee set up
by President Kennedy in 1962, that there may be as many
as 250 000 Americans addicted to barbiturates. Indeed, the
USA currently produces 30 barbiturate pills per inhabitant
per year (Escohotado 1996). Some barbiturates (amobarbital
and pentobarbital) have even found their way into mixtures
with amphetamine derivatives (goofballs), such as
Dexamyl
®, a combination of dextroamphetamine and
amobarbital.
In relation to the frequent cases of death by overdose,
given the small therapeutic margin of these substances, it
should be pointed out that this was a common method in
suicide attempts. It suffices to recall, in this regard, the
famous case of Marilyn Monroe, on whose death certificate
it clearly states “acute poisoning by overdose of bar-
biturates” (Figure 7). The lethal effect of these compounds
was such that a mixture of barbiturates with other substances
Figure 7 Death certificate of the actress Marilyn Monroe, issued on 28th August 1962. The circles indicate cause of death (“Acute barbiturate poisoning. Ingestion of
overdose”) and the intentionality (“Probable suicide”).
Figure 6 Evolution of annual barbiturates production in USA for the period
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was even employed in some USA states for the execution
of prisoners sentenced to death. Furthermore, there are
classic reports of fatal overdose due to the “automatism
phenomenon”, whereby the patient would take his or her
dose, only to forget that he or she had already taken it, given
the amnesic effect of the drug, and take it again, this process
being repeated several times (Richards 1934). Figure 8
shows the evolution of number of deaths (accidental or
suicide) by barbiturate overdose in England and Wales for
the period 1905–1960. In this regard, and in the city of New
York alone, in the period 1957–1963, there were 8469 cases
of barbiturate overdose, with 1165 deaths (Sharpless 1970),
whilst in the United Kingdom, between 1965 and 1970, there
were 12 354 deaths attributed directly to barbiturates
(Barraclough 1974). These data should not surprise us, since
in a period of just one year (1968), 24.7 million prescriptions
for barbiturates were issued in the United Kingdom (Plant
1981). In view of these data, the Advisory Council Campaign
in Britain took measures restricting the prescription of these
drugs. Meanwhile, the prescription of prolonged-acting
sedative barbiturates was strongly opposed through citizens’
action campaigns such as CURB (Campaign on the Use and
Restrictions of Barbiturates), especially active during the
1970s.
Furthermore, during the 1950s, when the use of
barbiturates was at its peak, there took place a veritable
revolution in the approach to psychiatric disorders, thanks
to the introduction into clinical practice of the first
pharmacological tools aimed specifically at treating these
patients (Caldwell 1970; Jacobsen 1986; Ayd 1991;
Lehmann 1993; Frankenburg 1994; López-Muñoz et al
2000; Ban 2001; Healy 2002). This “psychopharmacological
revolution” began with the discovery and clinical use, from
1952, of chlorpromazine (López-Muñoz et al 2004),
culminating in the commercialization of the first
benzodiazepine, chlordiazepoxide, in 1960. The discovery
of benzodiazepines was actually made possible, in part, by
the 60 years of clinical and basic research provided by
barbiturates, whose therapeutic life, from that time on, began
to decline.
Barbiturates today
Currently, the use of barbiturates is circumscribed to quite
specific therapeutic applications (Charney et al 2001). Thus,
phenobarbital and butabarbital are still used as sedatives in
cases of gastrointestinal and asthmatic functional disorders,
as well as to antagonize the adverse central stimulant effects
of some drugs, such as ephedrine, dextroamphetamine, or
theophylline. Phenobarbital is also used in cases of
withdrawal syndromes of hypnosedative agents. In the field
of neurology, barbiturates (phenobarbital and primidone)
are still employed, not only in the treatment of certain types
of epilepsy (partial and tonic-clonic generalized seizures),
but also in the emergency treatment of some types of
convulsions, such as those associated with tetanus,
eclampsia, cerebral hemorrhage, status epilepticus, or
different forms of poisoning. As intravenous anesthetic
inducers, ultrashort-acting barbiturates are of use, mainly
thiopental and methohexital, the latter also being
administered rectally in children or as a sedative in some
diagnostic imaging explorations. Table 4 shows the
therapeutic applications of barbiturates that have survived
to the present day.
In addition to these approved indications, the barbiturates
present other current uses. Phenobarbital is capable of
improving the hepatic transport of bilirubin in patients with
hemolytic jaundice, so that it can be used in newborn babies
to treat hyperbilirubinemia and kernicterus. At a diagnostic
level, amobarbital, in low doses, can be injected directly
into the carotid artery prior to neurosurgery to identify the
dominant cerebral hemisphere. Finally, anesthetic doses of
barbiturates can attenuate post-surgical cerebral edemas and
have positive effects in cases of cardiac and cerebral
ischemia, reducing the size of the infarcted region.
Moreover, barbiturates have been used since the 1970s in
the management of acute traumatic brain injury in their
capacity to reduce intracranial pressure (Marshall et al
1979). The mechanism through which high-dose
barbiturates appear to exert their intracranial pressure-
lowering effects is double: reduction of metabolism (with



































Figure 8 Deaths from overdose of barbiturates in England and Wales during
the period 1905–1960 (Registrar-General’s Statistical Review for England and
Wales). Includes both accidental deaths and suicides. Adapted from Glatt (1962).Neuropsychiatric Disease and Treatment 2005:1(4) 341
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and modifications in vascular tone (Kassell et al 1980).
Additionally some direct neuroprotective effects, such as
membrane stabilization or inhibition of free radical-
mediated lipid peroxidation, have been postulated (Piatt and
Schiff 1984). Despite results of the multicenter randomized
clinical trial published by Eisenberg et al (1988) that
demonstrated the efficacy of high-dose barbiturates in
severely head-injured patients with intractable intracranial
pressure elevations, recent collaborations, based in Cochrane
methodology, concluded that there is no evidence of health
improvement in this type of patient (Roberts 2000).
The barbiturates introduced clinically one century ago
were the first pharmacological agents to have demonstrated –
 in an historical period that was therapeutically inhospitable –
 a real efficacy in different neuropsychiatric disorders. They
were the first-line treatment as hypnotics and anticonvulsants
during the first half of the 20th century. The clinical results
obtained in the last years in other indications such as the
treatment (acute or prophylactic) of traumatic brain injury,
although contradictory, seems to confirm that, from the
pharmacological perspective, the barbiturates continue
furnishing certain novelties and that in their history the last
page has not yet been written.
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